Novel sugar ureide and thioureide derivatives

Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

536 18, 536 22, A61K 3113, C07H 504

Patent

active

040256227

ABSTRACT:
Novel sugar ureide and thioureide derivatives are provided by this invention, which exhibit certain antibacterial activity against a variety of gram-positive and gram-negative bacteria and useful in therapeutic treatment of bacterial infections. The compounds have the formula ##STR1## wherein R.sub.1 is a monovalent residue of aldose, aldonic acid and their 2-amino derivatives, R.sub.2 is an aralkyl, heterocyclic, sulfamoylaryl, R.sub.3 CONH or R.sub.4 NH-- where R.sub.3 is a heterocyclic and R.sub.4 is an aryl group and Y is oxygen or sulfur atom, which are prepared by reacting an isocyanate or isothiocyanate of the formula R.sub.1 NC=Y with an amino compound of the formula R.sub.2 NH.sub.2.

REFERENCES:
patent: 2612497 (1952-09-01), Meijer
patent: 2967859 (1961-01-01), Osipow et al.
patent: 3027364 (1962-03-01), Knoevenagel
patent: 3135748 (1964-06-01), Sheehan
patent: 3149033 (1964-09-01), Clark
patent: 3158598 (1964-11-01), Morel

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Novel sugar ureide and thioureide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel sugar ureide and thioureide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel sugar ureide and thioureide derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-537603

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.